COVID Links
Curated & Updated Daily
As of late June 2026, NB.1.8.1 accounted for about 50% of globally submitted sequences (up from 35%), while XFG fell to about 17%. WHO continues to list JN.1 as a Variant of Interest and monitors NB.1.8.1, XFG, BA.3.2, and newly designated PQ.16.1.1 (July 27) as Variants Under Monitoring. No elevated severity signal has been reported.
Source WHO COVID-19 Dashboard [July 2026] — Support for: variant monitoring
FDA’s VRBPAC recommended a monovalent XFG (JN.1-lineage) composition for the 2026–2027 U.S. COVID-19 vaccine formula beginning fall 2026. The European Commission has authorized an XFG-adapted Pfizer-BioNTech vaccine. Current 2025–2026 vaccines remain available; high-risk groups should stay up to date.
Source FDA / WHO [July 2026] — Support for: vaccine guidance
Paxlovid remains the most widely available oral antiviral for high-risk adults and children 12+ and must be started within 5 days of symptoms. Remdesivir (Veklury) remains FDA-approved for hospitalized and high-risk outpatient use (start within 7 days). Check eligibility and drug interactions with your provider.
Source CDC — COVID-19 Treatment [July 2026] — Support for: treatment options
CDC advises travelers to review current COVID-19 Travel Health Notices before international trips. Recommendations include staying up to date on vaccines, carrying an antiviral prescription if eligible, and monitoring destination-specific transmission levels on the CDC Travelers' Health portal.
Source CDC Travelers' Health [July 2026] — Support for: travel planning